An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy
Hunter et al. engineer a high affinity, soluble variant of leukemia inhibitory factor receptor (LIFR) to serve as a ligand trap for the LIF cytokine. They further demonstrate that this engineered LIFR exhibits improved affinity relative to the wild-type receptor, leading to better disruption of LIF...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/c3dd515a153e4ff89d47ae646b6e90b2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sea el primero en dejar un comentario!